Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program

Trial Profile

Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POP
  • Sponsors Biogen
  • Most Recent Events

    • 28 Feb 2017 Planned End Date changed from 1 Aug 2022 to 1 Jan 2022.
    • 28 Feb 2017 Planned primary completion date changed from 1 Aug 2022 to 1 Jan 2022.
    • 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top